Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financi... (le operatingwith a lean overhead structu...)

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results

Date:11/10/2008

le operating with a lean overhead structure." Weiss continued, "We expect our cash burn to be approximately $3 million for the remaining three months of 2008, and intend to continue to focus our resources on creating value in our product portfolio."

On Tuesday, November 11, 2008, at 8:30am EST, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's third quarter financial results.

In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional dru
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
5. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
6. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
7. Bradmer announces 2008 third quarter operational and financial results
8. Hillenbrand, Inc. Announces Fourth-Quarter Earnings Release Date and Conference Call
9. TransTech Services Partners Inc. Announces Election of Dr. Ranga C. Krishna as a Director
10. URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards
11. Heska Announces Q3 2008 Results

Post Your Comments:

(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...

(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...

(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...

(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...

(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...

Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2 Health News:New Jersey Kids 'Kick Butts' on March 24 3 Health News:New Jersey Kids 'Kick Butts' on March 24 4 Health News:New Jersey Kids 'Kick Butts' on March 24 5 Health News:New Hampshire Kids 'Kick Butts' on March 24 2 Health News:New Hampshire Kids 'Kick Butts' on March 24 3 Health News:New Hampshire Kids 'Kick Butts' on March 24 4 Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2 Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3 Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4 Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5 Health News:Residency match results not encouraging for adults needing primary care 2 Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2 Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3

[0] New Jersey Kids 'Kick Butts' on March 24 [0] New Hampshire Kids 'Kick Butts' on March 24 [0] Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco [0] Residency match results not encouraging for adults needing primary care [0] Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years

... a part of a national team of scientists engaged ... treatment of inflammatory bowel disease. ,Her research ... Institutes of Health grant supporting the Food and Waterborne ... National Institutes of Allergy and Infectious Diseases. ,Some ...

... the growing menace of potentially lethal or harmful counterfeit ... a global health crisis. ,"There is a ... developing world," said Jo Harkness, of the International Alliance ... are shocking. Countering supply chains is vital." The call ...

... developed robotic hands, which they say can be controlled ... developed by Yukiyasu Kamitani and colleagues, mimics the movements ... magnetic resonance imaging (fMRI) of their brain activity, reported ... from the ATR Computational Neuroscience Laboratories in Kyoto and ...

... the San Francisco VA Medical Center and the University of California, San Francisco, poor literacy ... two times as likely to have poor health and poor health care access in people ... ... Elders with limited literacy, which the researchers define ...

... Jerome Blanchard a surgeon working at the Middlesex Hospital was ... woman//. The General Medical Council (GMC) panel found him ... The chairman of the panel Judith Worthington said that the ... not in the best interests of the patient. ...

... Raftery, a professor health technology assessment it is said that ... for Health and Clinical Excellence (NICE) was set up as ... the task of getting the best from NHS resources. It ... and Wales and recommends whether they should be used unreservedly, ...

Other Medicine News:Health News:Parasitic Worms Could Be Used To Treat Bowel Disease 2 Health News:Lower Literacy Puts Poor Health In Aging 2 Health News:Lower Literacy Puts Poor Health In Aging 3

Parasitic Worms Could Be Used To Treat Bowel Disease Action Urged Against Fake Medicines Japanese Scientists Develop Thought-Controlled Robotic Hands Lower Literacy Puts Poor Health In Aging Surgeon Suspended As He Removes the Wrong Kidney NICE Comes Under Attack

(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...

(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...

(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...

Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2 U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3 U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4 U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8 FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2 FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3 FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4 FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5 Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1 Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2 Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3 Exposure to lead tobacco smoke raises risk of ADHD 10856 1 Exposure to lead tobacco smoke raises risk of ADHD 10856 2 Measuring and modeling blood flow in malaria 61892 1 Measuring and modeling blood flow in malaria 61892 2

[0] U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter [0] Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts [0] FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels

... trial data for Perforomist(TM) Solution presented at,International ... Data from a Phase IIIb,clinical trial demonstrate ... provided prolonged bronchodilation,and increased patient satisfaction compared ... were presented today in Philadelphia,at CHEST 2008, ...

... bone mineral density at the,lumbar spine and total ... inhalation powder) and salmeterol, - Study provides ... patients,with COPD, PHILADELPHIA, Oct. 29 GlaxoSmithKline ... study of patients with,Chronic Obstructive Pulmonary Disease (COPD) ...

Other Medicine Technology:Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 2 Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 3 Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 4 Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 5 Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 6 Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 2 Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 3

Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Anti-Cardiolipin Antibody, IgG Anti-A Titer Angelman Syndrome 3a-Androstanediol glucuonide

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financi...(le operatingwith a lean overhead structu...),Health